Ensera and Argonaut Partner to Streamline Supply for Drug-Device Combination Products

The collaboration combines Argonaut’s aseptic fill finish capabilities with Ensera’s device assembly and packaging expertise helping customers simplify supply chains, reduce operational risks and speed up production timelines.

Argonaut provides aseptic fill-finish services for vials, syringes, and cartridges, along with analytical testing and stability studies. Ensera complements these services with device assembly, labeling, secondary packaging, kitting, serialization sterilization management and testing for vials and drug delivery devices.

Through the partnership customers can access a simplified quotation process that cover's services from both companies. They will also benefit from coordinated project management, helping ensure smooth collaboration between fill finish and device assembly activities throughout development, and manufacturing.

Argonaut has audited Enseras US facility and approved the company as a key supply chain partner. This reflects both companies commitment to maintaining high quality standards for clinical and commercial manufacturing programs.

The partnership is designed to address common challenges in the combination product market, including fragmented supply chains, limited manufacturing capacity for mid sized programs and the growing need to bring specialty biologics and biosimilars to market more quickly. By improving coordination across manufacturing stages, the companies aim to deliver a more efficient development and production process.

Read More:Persistent Announces Partnership with San Francisco Unicorns

Rick Hancock, CEO, Argonaut, commented, “More than ever, our clients are focused on developing their products in conjunction with autoinjectors to improve accessibility for patients. While this is a commendable goal, it adds complexity to supply chains. This partnership with Ensera eases that burden for sponsors. Just as our clients are focused on improving the patient experience, Argonaut is focused on improving our clients' experience.”

Jason Anderson, CEO of Ensera, said the partnership reflects both companies’ commitment to supporting pharmaceutical firms developing complex combination products, especially in low to mid-volume programs where flexibility and coordination are critical. By combining Ensera’s device assembly, and packaging expertise with Argonaut’s fill-finish capabilities the partnership aims to simplify key development and manufacturing stages, reduce risk and help customers move their products toward commercialization more efficiently.

About Ensera

Ensera is a global CDMO that supports pharmaceutical and medical device companies with device design, final assembly, labeling and secondary packaging for injectable products, including autoinjectors and pre-filled syringes. With GMP-compliant facilities across Europe, and the United States, the company specializes in low to medium volume production and offers integrated quality systems, and cold chain capabilities.

About Argonaut

Founded in 2016, Argonaut is a contract development and manufacturing organization (CDMO) specializing in aseptic fill finish services for vials, syringes and cartridges, from clinical development through commercial production. The company operates two fully automated, isolator based filling lines that meet Annex 1 and FDA requirements. It also uses high yield manufacturing processes and 100% weight checks to minimize product loss while providing onsite analytical testing and stability study services.

Read More:Landseed Receives $400K Social-Impact Investment